Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale

Trends in Molecular Medicine

Volumn 16, Issue 3, 2010, Pages 122-132

  Bagri, Anil ^a   Kouros Mehr, Hosein ^a   Leong, Kevin G ^a   Plowman, Greg D ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BIBF 1120; BMS 907351; BRIVANIB ALANINATE; CEDIRANIB; EXELIXIS; FLUOROURACIL; FOLINIC ACID; IMC 1121B; IMCLONE; KRN 951; OXALIPLATIN; PAZOPANIB; PLACENTAL GROWTH FACTOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TIVOZANIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VOTRIENT; XL 184;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MODEL; CANCER SURVIVAL; CARCINOID; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SARCOMA; STOMACH CANCER; THYROID CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949275202     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.01.004     Document Type: Review

References (82)

1. Mano M.S., and Duhoux F. Colon cancer: update on adjuvant therapy. Clin. Colorectal Cancer 7 (2008) 178-183
2. Fisher B., et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N. Engl. J. Med. 305 (1981) 1-6
3. Romond E.H., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
4. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
5. Hurwitz H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
6. Giantonio B.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25 (2007) 1539-1544
7. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355 (2006) 2542-2550
8. Miller K., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357 (2007) 2666-2676
9. Friedman H.S., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27 (2009) 4733-4740
10. Kreisl T.N., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27 (2009) 740-745
11. Jenab-Wolcott J., and Giantonio B.J. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin. Biol. Ther. 9 (2009) 507-517
12. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 28 (2006) 1779-1802
13. Bagri A., et al. Neuropilins in tumor biology. Clin. Cancer Res. 15 (2009) 1860-1864
14. Hicklin D.J., and Ellis L. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
15. Vredenburgh J.J., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13 (2007) 1253-1259
16. Numnum T.M., et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol. 102 (2006) 425-428
17. Chong G., and Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J. Clin. Oncol. 23 (2005) 9063-9066
18. Ellis L.M., et al. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J. Clin. Oncol. 23 (2005) 4853-4855
19. O'Connor J., et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor. Clin. Cancer Res. 15 (2009) 6674-6682
20. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
21. Kerbel R. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 312 (2006) 1171-1175
22. Teicher B.A. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics→mechanism(s) of interaction). Cancer Metastasis Rev. 15 (1996) 247-272
23. Boucher Y., et al. Tumor angiogenesis and interstitial hypertension. Cancer Res. 56 (1996) 4264-4266
24. Nakahara T., et al. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 66 (2006) 1434-1445
25. Tong R.T., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
26. Yuan F., et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14765-14770
27. Yuan F., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
28. Flessner M.F., et al. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin. Cancer Res. 11 (2005) 3117-3125
29. Gerber H.-P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
30. Bao S., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66 (2006) 7843-7848
31. Jiang, H. et al. (2010) Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Pathways mediating VEGF-independent tumor angiogenesis. Cancer Invest., doi:10.3109/07357900902744510
32. Yang L., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004) 409-421
33. Shaked Y., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
34. de Boer M., et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med. 361 (2009) 653-663
35. Jemal A., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
36. Bergers G., and Benjamin L. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
37. Indraccolo S., et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4216-4221
38. Almog N., et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 69 (2009) 836-844
39. Naumov G.N., et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl. Cancer Inst. 98 (2006) 316-325
40. Mabuchi S., et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin. Cancer Res. 14 (2008) 7781-7789
41. Kolinsky K., et al. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. Mol. Cancer Ther. 8 (2009) 75-82
42. Mathieu, V. et al. (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10, 1383-1392
43. Relf M., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57 (1997) 963-969
44. Casanovas O., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
45. Holash J., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
46. Du R., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008) 206-220
47. Nguyen D., et al. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9 (2009) 274-284
48. Wieser E., et al. Access of tumor-derived macromolecules and cells to the blood: an electron microscopical study of structural barriers in microvessel clusters in highly malignant primary prostate carcinomas. Prostate 62 (2005) 123-132
49. Inai T., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165 (2004) 35-52
50. Batchelor T.T., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
51. Jain R., et al. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67 (2007) 2729-2735
52. Xian X., et al. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116 (2006) 642-651
53. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3 (2003) 453-458
54. Nikolova G., et al. The vascular niche and its basement membrane. Trends Cell Biol. 17 (2007) 19-25
55. Hiratsuka S., et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8 (2006) 1369-1375
56. Psaila B., and Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9 (2009) 285-293
57. Kaplan R., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
58. Ebos J.M., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009) 232-239
59. Gao D., et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319 (2008) 195-198
60. Dawson M.R., et al. VEGFR1-activity-independent metastasis formation. Nature 461 (2009) E4 discussion E5
61. Kienast, Y. et al. (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116-122
62. Fidler I.J. Critical determinants of metastasis. Semin. Cancer Biol. 12 (2002) 89-96
63. Podsypanina K., et al. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321 (2008) 1841-1844
64. Kozlowski J.M., et al. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 44 (1984) 3522-3529
65. Warren R.S., et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995) 1789-1797
66. Schabel F.M. Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40 (1977) 558-568
67. Tester A.M., et al. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin. Exp. Metastasis 18 (2000) 553-560
68. Hirayama R., et al. Different metastatic modes of malignant melanoma implanted in the ear of young and old mice. Cancer Immunol. Immunother. 18 (1984) 209-214
69. Hoshida T., et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 66 (2006) 8065-8075
70. Schackert H.K., and Fidler I.J. Development of an animal model to study the biology of recurrent colorectal cancer originating from mesenteric lymph system metastases. Int. J. Cancer 44 (1989) 177-181
71. Takahashi Y., et al. Progressive upregulation of metastasis-related genes in human colon cancer cells implanted into the cecum of nude mice. Oncol. Res. 8 (1996) 163-169
72. House A.K., and Maley M.A. Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model. J. R. Soc. Med. 76 (1983) 833-840
73. Singh M., and Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res. 12 (2006) 5312-5328
74. McCart A.E., et al. Apc mice: models, modifiers and mutants. Pathol. Res. Pract. 204 (2008) 479-490
75. Lin E.Y., et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163 (2003) 2113-2126
76. Guy C.T., et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10578-10582
77. Kouros-Mehr H., et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13 (2008) 141-152
78. Benson A.B. Chemotherapy: adding oxaliplatin to the equation. Nat. Rev. Clin. Oncol. 6 (2009) 620-622
79. Ferrara N. (2009) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev., doi:10.1016/j.cytogfr.2009.11.003
80. Allegra, C. et al. (2009) Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 27, 3385-3390
81. Paez-Ribes M., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
82. Stockmann C., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456 (2008) 814-818